Seiler Till, Döhner Hartmut, Stilgenbauer Stephan
Department of Internal Medicine III, University of Ulm, Ulm, Germany.
Semin Oncol. 2006 Apr;33(2):186-94. doi: 10.1053/j.seminoncol.2006.01.017.
Chronic lymphocytic leukemia (CLL) follows an extremely variable clinical course with survival ranging from months to decades. Available treatments can often induce remissions, but eventually all patients relapse. Recently, there has been major progress in the identification of molecular and cellular markers that may predict the tendency for disease progression in patients with CLL. Genomic aberrations, the mutational profile of IgVH genes and its surrogate marker ZAP-70 expression, and serum markers like B2-microglobulin (beta2-MG) and thymidine kinase (TK) provide prognostic information for individual patients independently of clinical disease characteristics. These molecular markers are about to enter the stage of risk stratification for individual patients in clinical trials.
慢性淋巴细胞白血病（CLL）的临床病程变化极大，生存期从数月到数十年不等。现有的治疗方法常常能诱导缓解，但最终所有患者都会复发。最近，在识别可能预测CLL患者疾病进展倾向的分子和细胞标志物方面取得了重大进展。基因组畸变、IgVH基因的突变谱及其替代标志物ZAP-70表达，以及诸如β2-微球蛋白（beta2-MG）和胸苷激酶（TK）等血清标志物，独立于临床疾病特征为个体患者提供预后信息。这些分子标志物即将进入临床试验中个体患者风险分层的阶段。
